Congress Asset Management Co. MA Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Congress Asset Management Co. MA trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 16.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 917,825 shares of the company’s stock after selling 176,352 shares during the period. […]

Related Keywords

Maryland ,United States ,San Diego ,California ,Wyliew Vale ,Kevinc Gorman ,Piper Sandler ,Neurocrine Biosciences ,Matt Abernethy ,Congress Asset Management Co ,Piershale Financial Group Inc ,Patriot Financial Group Insurance Agency ,Citigroup ,Exchange Commission ,Nasdaq ,Neurocrine Biosciences Company Profile ,Exchange Traded Concepts ,Morgan Stanley ,Neurocrine Biosciences Inc ,Barclays ,Hennion Walsh Asset Management Inc ,Congress Asset Management ,Get Rating ,Asset Management ,State Retirement ,Pension System ,Traded Concepts ,Financial Group Insurance Agency ,Financial Group ,Walsh Asset Management ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,